8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Immunopathologic features predict renal function at baseline and follow-up in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). The interstitial infiltrate consists predominantly of T lymphocytes, but their pathophysiologic significance is unclear, especially in light of the success of B-cell-directed therapy. Methods: Renal biopsies from 33 patients treated with cyclophosphamide (CYC; n = 17) or rituximab (RTX; n = 16) in the RTX in ANCA-associated vasculitis (RAVE) trial were classified according to the new ANCA GN classification. T- and B-cell infiltration in the interstitium was assessed by immunostaining for CD3 and CD20. Correlations of clinical and histologic parameters with renal function at set time points were examined. Results: The mean (SD) baseline estimated glomerular filtration rate was 36 (20) mL/min/1.73 m<sup>2</sup>. ANCA GN class distribution was 46% focal, 33% mixed, 12% sclerotic and 9% crescentic. The interstitial infiltrate consisted of >50% CD3 positive cells in 69% of biopsies, but >50% CD20 positive cells only in 8% of biopsies. In a multiple linear regression model, only baseline glomerular filtration rate (GFR) correlated with GFR at 6, 12, and 18 months. Interstitial B- and T-cell infiltrates had no significant impact on long-term prognosis, independent of the treatment limb. A differential effect was noted only at 6 months, where a dense CD3 positive infiltrate predicted lower GFR in the RTX group and a CD20 positive infiltrate predicted higher GFR in the CYC group. Conclusions: In ANCA-associated GN, the interstitial infiltrate contains mainly T lymphocytes. However, it is neither reflecting baseline renal function nor predictive of response to treatment, regardless of the immunosuppression regimen employed.

          Related collections

          Author and article information

          Journal
          AJN
          Am J Nephrol
          10.1159/issn.0250-8095
          American Journal of Nephrology
          S. Karger AG
          0250-8095
          1421-9670
          2017
          September 2017
          08 September 2017
          : 46
          : 3
          : 231-238
          Affiliations
          aDivision of Nephrology and Division of Rheumatology, Johns Hopkins University, Baltimore, MD, bDepartment of Anatomic Pathology, cDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, and dDivision of Nephrology and Hypertension, Rochester, MN, eImmune Tolerance Network, Bethesda, MD, fRheumatology Division, Hospital for Special Surgery, New York, NY, gDivision of Rheumatology and Immunology, Duke University, Durham, NC, hDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, iDivision of Rheumatology, Boston University Medical Center, and jRheumatology Unit, Massachusetts General Hospital, Boston, MA, kDivision of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, and lCenter for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, USA; mDivision of Nephrology, AZ Sint-Jan Brugge, Brugge, Belgium; nDepartment of Rheumatology and Clinical Immunology University Medical Center, University of Groningen, Groningen, The Netherlands
          Author notes
          *Fernando C. Fervenza, MD, PhD, Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55901 (USA), E-Mail fervenza.fernando@mayo.edu
          Article
          480443 Am J Nephrol 2017;46:231-238
          10.1159/000480443
          6640633
          28881339
          f05050e6-f355-4fd6-abb8-f4b893a25fd2
          © 2017 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 05 July 2017
          : 18 August 2017
          Page count
          Figures: 3, Tables: 3, References: 26, Pages: 8
          Categories
          Original Report: Patient-Oriented, Translational Research

          Cardiovascular Medicine,Nephrology
          B cells,T cells,Rituximab,Antineutrophil cytoplasmic antibody,Vasculitis

          Comments

          Comment on this article